Shanghai Junshi Biosciences Co Ltd - Asset Resilience Ratio
Shanghai Junshi Biosciences Co Ltd (688180) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Junshi Biosciences Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Shanghai Junshi Biosciences Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Shanghai Junshi Biosciences Co Ltd asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Junshi Biosciences Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688180 liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥600.81 Million | 4.85% |
| Total Liquid Assets | CN¥600.81 Million | 4.85% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Junshi Biosciences Co Ltd maintains only 4.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Junshi Biosciences Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Junshi Biosciences Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Shanghai Junshi Biosciences Co Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.85% | CN¥600.81 Million ≈ $87.92 Million |
CN¥12.38 Billion ≈ $1.81 Billion |
+0.87pp |
| 2024-12-31 | 3.99% | CN¥430.51 Million ≈ $63.00 Million |
CN¥10.80 Billion ≈ $1.58 Billion |
+3.99pp |
| 2020-12-31 | 0.00% | CN¥17.00K ≈ $2.49K |
CN¥8.01 Billion ≈ $1.17 Billion |
0.00pp |
| 2019-12-31 | 0.00% | CN¥17.00K ≈ $2.49K |
CN¥4.42 Billion ≈ $647.14 Million |
-0.13pp |
| 2018-12-31 | 0.13% | CN¥5.52 Million ≈ $807.16K |
CN¥4.26 Billion ≈ $622.98 Million |
-11.96pp |
| 2017-12-31 | 12.09% | CN¥147.43 Million ≈ $21.57 Million |
CN¥1.22 Billion ≈ $178.48 Million |
-20.42pp |
| 2016-12-31 | 32.50% | CN¥373.47 Million ≈ $54.65 Million |
CN¥1.15 Billion ≈ $168.14 Million |
-38.21pp |
| 2014-12-31 | 70.71% | CN¥235.44 Million ≈ $34.45 Million |
CN¥332.94 Million ≈ $48.72 Million |
-- |
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more